Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Bicara Therapeutics Fourth Quarter and Full Year 2025 Earnings Call.
Bicara Therapeutics Inc. (BCAX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 6,955,993 | $117,069,362 | 1.2% | |
| 2. | Siren L.L.C. Raymond Debbane | 5,216,969 | $87,801,588 | 2.62% | |
| 3. | Vestal Point Capital Ryan Wilder | 3,575,000 | $60,167,250 | -30% | 2.05% |
| 4. | Deep Track Capital David Kroin | 2,614,004 | $43,993,687 | +8% | 0.78% |
| 5. | Citadel Investment Group Ken Griffin | 772,258 | $12,997,102 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 300,000 | $4,800,000.00 | 4,603,418 | 2026-02-26 | Filing | |
| $18.00 | 152,480 | $2,744,640.00 | 2,652,575 | 2024-09-16 | Filing | |
| $18.00 | 1,680,520 | $30,249,360.00 | 4,303,418 | 2024-09-16 | Filing | |
| $18.00 | 35,000 | $630,000.00 | 897,587 | 2024-09-17 | Filing | |
| $18.00 | 35,000 | $630,000.00 | 897,587 | 2024-09-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.95 | 5,500 | $104,229.40 | 55,286 | 2026-03-25 | Filing | |
| $18.52 | 9,200 | $170,348.12 | 145,355 | 2026-03-23 | Filing | |
| $18.95 | 1,596 | $30,246.27 | 339,392 | 2026-03-20 | Filing | |
| $18.78 | 6,905 | $129,704.90 | 339,392 | 2026-03-19 | Filing | |
| $18.84 | 6,499 | $122,414.51 | 339,392 | 2026-03-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,344 | $205,742 | 0.03% | |
| 2. | 1,400 | $27,846 | 0% | |
| 3. | 434 | $8,632 | 0% | |
| 4. | 80 | $1,640 | 0% | |
| 5. | 32 | $636 | 0% |
News See All
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
Bicara Therapeutics Inc. (NASDAQ:BCAX) is a clinical-stage biopharmaceutical company that develops innovative bifunctional antibody therapies for solid tumors.
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
The company's abstract provided a number of encouraging results for HPV-negative patients.
Hedge Fund Resource Center